(Lebanon, NH, 4/24/14) Dartmouth has been awarded one of 30 grants from the National Cancer Institute (NCI) to serve as a Lead Academic Participating Site in its new National Clinical Trials Network (NCTN). Award recipients are a select groups of investigators charged with distributing resources in a more effective way across fewer cooperative groups.
The NCTN grant system reflects recommendations from a 2010 Institute of Medicine Report. It streamlines operations to achieve four goals:
Through a consolidation of operational resources, the NCTN untangles behind-the-scenes red tape by using:
Everyonepatients, providers, and family memberswants to see faster access to new treatments for cancer, said Konstantin H. Dragnev, MD, principal investigator for the Dartmouth-Hitchcock Norris Cotton Cancer Center site. This new framework will cut the startup time for a clinical trial by 75 percent in some cases. It removes obstacles we used to face for reporting and oversight, so we can now offer therapeutic advances to patients sooner.
As a Lead Academic Participating Site, Norris Cotton Cancer Center will be charged with enhancing participation in NCI randomized phase three clinical trials, the gold standard in cancer research for establishing new treatments for a five year period. Participating sites provide scientific leadership in the development of clinical trials, while meeting performance benchmarks for quality clinical research. Dartmouth will oversee involvement and participation from affiliated patient enrollment settings in New Hampshire, Vermont, and other states.
As a group we can achieve more than we can individually, said Dragnev of the co-operative groups in the nationwide network. Urban and rural residents can participate in the same study, which expands our ability to include a more diverse population in an individual study. The Dartmouth-led affiliations also mean greater access to new therapies in relatively remote areas served in northern New England.
The new network represents an unmatched effort to integrate and streamline the process of cancer clinical trials research, said James Doroshow, MD, deputy director for clinical and translational research at NCI. The conduct of NCI-supported trials, which are publicly funded, involves a complex system of designing, reviewing, and initiating studies. The new NCTN replaces a structure that was more than 55 years old.
NCTN employs an inclusive process for generating studies and conducting clinical trials using broad representation from the oncology field, including academic researchers, as well as professional organizations, patients, and advocates.
The Network has combined smaller cooperative groups with specialized foci, such as, pediatric, breast/bowel, or gynecological cancers. These consolidated cooperative groups allow for closer communication and collaboration among researchers doing work in the same area. The newly announced Lead Academic Participating Sites will serve as common outlets for offering trials originating from any of these groups.
Norris Cotton Cancer Centers selection as a Lead Participating Site affirms our role as a national leader in cancer research, said Mark Israel, MD, director, Norris Cotton Cancer Center. We are among an elite group of investigators conducting nationally the highest caliber of scientific research.
|Contact: Donna Dubuc|
The Geisel School of Medicine at Dartmouth